

Response to: Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Mora *et al*

Paula Martinez Sanz ¹, Dieke J van Rees,¹ Hanke L Matlung,¹ Godelieve A M Tytgat,² Katka Franke¹

To cite: Martinez Sanz P, van Rees DJ, Matlung HL, *et al*. Response to: Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Mora *et al*. *Journal for ImmunoTherapy of Cancer* 2021;**9**:e003983. doi:10.1136/jitc-2021-003983

Accepted 17 October 2021



- ▶ <http://dx.doi.org/10.1136/jitc-2021-003751>
- ▶ <http://dx.doi.org/10.1136/jitc-2020-002259>



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands

²Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

Correspondence to

Paula Martinez Sanz;
p.martinezsan@sanquin.nl

Dear Editor,

We appreciate the interest of Dr Mora and Dr Chantada¹ in our recently published work proposing granulocyte colony-stimulating factor (G-CSF) as a suitable alternative to improve antibody treatment of patients with high-risk neuroblastoma.² The authors strongly advocate finding ways to increase accessibility of granulocyte-monocyte colony-stimulating factor (GM-CSF, sargramostim), used in combination with dinutuximab in North America, also in countries where this treatment is currently not available. We fully agree that all relevant stakeholders should participate in finding a permanent solution to prevent potentially suboptimal treatment of patients with high-risk neuroblastoma in the absence of sargramostim. Part of this solution might be identification of another suitable cytokine with potential to increase neutrophil-mediated killing of neuroblastoma cells as the inaccessibility of sargramostim may remain a problem in the future.

As neutrophils have been shown to be the main effector cells in the destruction of dinutuximab-opsonized GD2⁺ cells,³ the choice for a cytokine that increases production, release, and activation state of these immune cells is a highly reasonable one. Dr Mora and Dr Chantada urge for caution in using G-CSF as an alternative as this cytokine is not interchangeable with GM-CSF and may pose safety risks as previously suggested.⁴⁻⁶ We agree that G-CSF cannot fully recapitulate the biological properties of GM-CSF, but it is in our opinion the next closest alternative and deserves proper evaluation in follow-up clinical studies. Two of the studies reporting detrimental effects of G-CSF in patients with

neuroblastoma were published by the same group^{5,6} and suggest caution in administering G-CSF during chemotherapy cycles. These findings triggered opposed responses in the clinical field.⁷ The main argument was that concentrations of G-CSF used in preclinical studies were much higher than equivalent dosages used in patients. Also, use of G-CSF to support intensive induction chemotherapy regimens had been shown to be safe and not affecting overall tumor response to therapy.⁷ We have shown in our study that long-term in vitro exposure to G-CSF in high concentrations does not alter the phenotype of neuroblastoma cell lines and primary cells, nor their sensitivity to dinutuximab-mediated killing, further suggesting safety of such a treatment for patients with neuroblastoma.

As proposed in our study, a thorough clinical evaluation of safety, clinical efficacy and effect on overall survival of G-CSF in combination with dinutuximab in patients with high-risk neuroblastoma should be performed, ideally in a randomized and multicenter clinical trial.

Sincerely,

Paula Martinez Sanz, MSc

Dieke van Rees, MSc

Hanke L. Matlung, PhD

Godelieve A M. Tytgat, PhD

Katka Franke, PhD

Contributors All authors reviewed, revised, and approved this response letter.

Competing interests None declared.

Patient consent for publication Not applicable.

Provenance and peer review Commissioned; internally peer reviewed.



Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Paula Martinez Sanz <http://orcid.org/0000-0002-3564-0505>

REFERENCES

- 1 Mora J, Chantada GL. Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Martinez Sanz *et al.* *J Immunother Cancer* 2021. doi:10.1136/jitc-2021-003751
- 2 Martinez Sanz P, van Rees DJ, van Zogchel LMJ, *et al.* G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment. *J Immunother Cancer* 2021;9:e002259.
- 3 Barker E, Mueller BM, Handgretinger R, *et al.* Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. *Cancer Res* 1991;51:144–9.
- 4 Gay AN, Chang S, Rutland L, *et al.* Granulocyte colony stimulating factor alters the phenotype of neuroblastoma cells: implications for disease-free survival of high-risk patients. *J Pediatr Surg* 2008;43:837–42.
- 5 Hsu DM, Agarwal S, Benham A, *et al.* G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic. *Cancer Res* 2013;73:4134–46.
- 6 Agarwal S, Lakoma A, Chen Z, *et al.* G-CSF promotes neuroblastoma tumorigenicity and metastasis via STAT3-dependent cancer stem cell activation. *Cancer Res* 2015;75:2566–79.
- 7 Maris JM, Healy J, Park J, *et al.* G-CSF is a cancer stem cell-specific growth Factor-Letter. *Cancer Res* 2015;75:3991.